Baird Medical to Participate in the AAES 2025 Annual Meeting
Baird Medical (NASDAQ: BDMD), a leader in Microwave Ablation (MWA) technology, announces its participation in the 45th Annual Meeting of the American Association of Endocrine Surgeons (AAES). The event will take place from May 17-19, 2025, at the Baird Center in Milwaukee, Wisconsin.
The AAES Annual Meeting, North America's premier gathering of endocrine surgeons, focuses on advancing endocrine surgery through research presentations, expert panels, and discussions on thyroid diseases, parathyroid, adrenal glands, and endocrine pancreas. Baird Medical's participation underscores the importance of its MWA technology in minimally invasive treatments for endocrine conditions, particularly thyroid nodules.
Baird Medical (NASDAQ: BDMD), leader nella tecnologia di Ablazione a Microonde (MWA), annuncia la sua partecipazione al 45° Incontro Annuale dell'American Association of Endocrine Surgeons (AAES). L'evento si terrà dal 17 al 19 maggio 2025 presso il Baird Center di Milwaukee, Wisconsin.
Il Meeting Annuale AAES, il principale raduno nordamericano di chirurghi endocrini, è dedicato all'avanzamento della chirurgia endocrina attraverso presentazioni di ricerca, panel di esperti e discussioni su malattie della tiroide, paratiroidi, ghiandole surrenali e pancreas endocrino. La partecipazione di Baird Medical sottolinea l'importanza della sua tecnologia MWA nei trattamenti minimamente invasivi per condizioni endocrine, in particolare i noduli tiroidei.
Baird Medical (NASDAQ: BDMD), líder en tecnología de Ablación por Microondas (MWA), anuncia su participación en la 45ª Reunión Anual de la American Association of Endocrine Surgeons (AAES). El evento se llevará a cabo del 17 al 19 de mayo de 2025 en el Baird Center en Milwaukee, Wisconsin.
La Reunión Anual de la AAES, el principal encuentro de cirujanos endocrinos en Norteamérica, se centra en avanzar la cirugía endocrina mediante presentaciones de investigación, paneles de expertos y discusiones sobre enfermedades de tiroides, paratiroides, glándulas suprarrenales y páncreas endocrino. La participación de Baird Medical destaca la importancia de su tecnología MWA en tratamientos mínimamente invasivos para condiciones endocrinas, especialmente nódulos tiroideos.
Baird Medical (NASDAQ: BDMD), 마이크로웨이브 절제술(MWA) 기술의 선두주자인 이 회사는 제45회 미국 내분비외과학회(AAES) 연례회의에 참가한다고 발표했습니다. 행사는 2025년 5월 17일부터 19일까지 위스콘신주 밀워키에 위치한 베어드 센터에서 열립니다.
AAES 연례회의는 북미 내분비외과 의사들의 주요 모임으로, 연구 발표, 전문가 패널, 갑상선 질환, 부갑상선, 부신, 내분비 췌장에 관한 토론을 통해 내분비 수술의 발전에 중점을 둡니다. 베어드 메디컬의 참여는 특히 갑상선 결절 치료에 있어 최소 침습 내분비 질환 치료에 MWA 기술의 중요성을 강조합니다.
Baird Medical (NASDAQ : BDMD), leader dans la technologie d'ablation par micro-ondes (MWA), annonce sa participation au 45e congrès annuel de l'American Association of Endocrine Surgeons (AAES). L'événement se tiendra du 17 au 19 mai 2025 au Baird Center de Milwaukee, Wisconsin.
Le congrès annuel de l'AAES, principal rassemblement nord-américain des chirurgiens endocriniens, se concentre sur l'avancement de la chirurgie endocrine à travers des présentations de recherche, des panels d'experts et des discussions sur les maladies de la thyroïde, des parathyroïdes, des glandes surrénales et du pancréas endocrinien. La participation de Baird Medical souligne l'importance de sa technologie MWA dans les traitements peu invasifs des affections endocriniennes, en particulier les nodules thyroïdiens.
Baird Medical (NASDAQ: BDMD), ein führendes Unternehmen im Bereich der Mikrowellenablation (MWA)-Technologie, gibt seine Teilnahme am 45. Jahreskongress der American Association of Endocrine Surgeons (AAES) bekannt. Die Veranstaltung findet vom 17. bis 19. Mai 2025 im Baird Center in Milwaukee, Wisconsin, statt.
Das AAES-Jahrestreffen, die wichtigste Tagung nordamerikanischer endokriner Chirurgen, konzentriert sich auf die Weiterentwicklung der endokrinen Chirurgie durch Forschungspräsentationen, Expertenpanels und Diskussionen zu Schilddrüsenerkrankungen, Nebenschilddrüse, Nebennieren und endokrinem Pankreas. Die Teilnahme von Baird Medical unterstreicht die Bedeutung ihrer MWA-Technologie für minimalinvasive Behandlungen endokriner Erkrankungen, insbesondere von Schilddrüsenknoten.
- None.
- None.
The AAES Annual Meeting is widely regarded as the premier gathering of endocrine surgeons in
Baird Medical's presence at the AAES 2025 meeting highlights the growing significance of its MWA technology in the evolving landscape of minimally invasive treatment options for endocrine conditions, particularly thyroid nodules. The participation provides an excellent opportunity for the Company to engage with key opinion leaders in endocrine surgery, share clinical updates on its MWA systems, and contribute to discussions on innovative patient care strategies.
The Company views the AAES Annual Meeting as a crucial opportunity to gain firsthand insights into cutting-edge surgical advancements and evolving clinical trends in endocrine care. This engagement supports Baird Medical's strategic initiatives, fosters valuable collaborations, and reinforces its commitment to developing effective, minimally invasive treatment solutions for patients with endocrine disorders.
Baird Medical remains committed to supporting the endocrine surgery community and advancing patient care through technological innovation. The Company looks forward to collaborating with AAES members and contributing to the scientific exchange at the 2025 meeting in
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the
The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-to-participate-in-the-aaes-2025-annual-meeting-302445680.html
SOURCE BDMD
FAQ
What is the purpose of Baird Medical's (BDMD) participation in AAES 2025?
When and where is the AAES 2025 Annual Meeting taking place?
What is Baird Medical's (BDMD) main technology focus?
What topics will be covered at the AAES 2025 Annual Meeting?
